ArticleCell reports. Medicine2021
Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis.
Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Mitigating IAPA mortality in the ICU: is it time for personalized immunotherapy?Critical care (London, England) · 2026Article
- Aspergillus fumigatus biology, immunopathogenicity and drug resistance.Nature reviews. Microbiology · 2025Review
- Article
- Towards a holistic approach to pulmonary infections. Insights from the Sixth Annual Meeting of Spanish Experts 2024.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Review
- Siglec15 in blood system diseases: from bench to bedside.Frontiers in immunology · 2024Review
- Uncloaking the viral glycocalyx: How do viruses exploit glycoimmune checkpoints?Advances in virus research · 2024Review
- Pathogenicity and virulence ofVirulence · 2023Review
- Dysregulated Pulmonary Inflammatory Responses Exacerbate the Outcome of Secondary Aspergillosis Following Influenza.bioRxiv : the preprint server for biology · 2023Article
- Development of a Corticosteroid-Immunosuppressed Mouse Model to Study the Pathogenesis and Therapy of Influenza-Associated Pulmonary Aspergillosis.The Journal of infectious diseases · 2023Article
- Immunity to fungi in the lung.Seminars in immunology · 2023Review
- A signature of differential gene expression in bronchoalveolar lavage fluid predicts mortality in influenza-associated pulmonary aspergillosis.Intensive care medicine · 2023Article
- Mechanistic Basis of Super-Infection: Influenza-Associated Invasive Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Novel Clinical and Laboratorial Challenges in Aspergillosis.Microorganisms · 2022Article
- Pathogenesis of Respiratory Viral and Fungal Coinfections.Clinical microbiology reviews · 2022Review
- Defective antifungal immunity in patients with COVID-19.Frontiers in immunology · 2022Review
- Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2021Article
- Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model.Virulence · 2021Article
- Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.Intensive care medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza-associated pulmonary aspergillosis (IAPA) has been reported increasingly since the advent of use of neuraminidase (NA) inhibitors following the 2009 influenza pandemic. We hypothesize that blocking host NA modulates the immune response against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.